Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.

Irbesartan in patients with heart failure and preserved ejection fraction.

Collaborators (365)

Carson PE, Massie BM, McKelvie R, McMurray J, Komajda M, Zile MR, Ptaszynska A, Staiger C, Cokkinos DV, Cornel JM, Dahlström U, Dalby A, Diaz R, Sanchez Diaz CJ, Dietz R, Edes I, Follath F, Gomes RS, González-Juanatey JR, Hradec J, Juilliere Y, Kober L, Kitzman DW, Krum H, Mareev V, McDonagh T, McDonald K, Mesquita ET, O'Connor CM, Otterstad JE, Ponikowski P, Rouleau JL, Tavazzi L, Vanhaecke J, Goldstein S, Cohn J, Julian D, Leizorovicz A, Neaton J, Zile M, White M, Gaasch W, Haass M, Little W, Lopez-Sendon J, Anand I, Miller A, Teerlink J, Diaz R, Fernandez A, Ahuad Guerrero A, Hershon A, Kuschnir E, Marzetti E, Nul D, Perna E, Paolasso E, Krum H, Amerena J, Colquhoun D, Cross D, Jeffery I, Krum H, Marwick T, Rees D, Sindone A, Singh B, Waites J, Walsh W, Vanhaecke J, Boutefeu J, Boxho G, Coucke F, El Allaf E, Geukens R, Gillebert T, Goethals M, Van Mieghem W, Vanhaecke J, Mesquita E, Albuquerque D, DePaola A, Feitosa G, Saraiva JF, Mesquita E, Moreira M, Rassi S, Xavier SS, Rouleau J, Constance C, Davies E, Fortin C, Harvey P, Isaac D, Klinke P, Kwok K, Leader R, Ma P, McKelvie R, Moe G, Mukherjee A, Parker J, Proulx G, Savard D, St-Maurice F, Yao L, Hradec J, Drazka J, Fridl P, Hradec J, Skalicka H, Kober L, Bronnumschou J, Torp-Pedersen C, Juilliere Y, Amat G, Bauer F, Bouvier J, Charbonnier B, Demarcq J, Fouche R, Funck F, Genest M, Juilliere Y, Kahn J, Ketelers R, Komajda M, Martelet M, Olive T, Poulard J, Richard M, Roynard JL, Dietz R, Angermann C, Boehm M, Figulla H, Freytag F, Goedel-Meinen L, Hein J, Hengstenberg C, Horacek T, Monti J, Muenzel T, Pieske B, Olbrich H, Rachor M, Schultheiss H, Sechtem U, Stahl H, Stangl K, Stempfle H, Willenbrock R, Wunderlich J, Cokkinos D, Alexopoulos D, Kardaras F, Kremastinos D, Nanas I, Edes I, Buza T, Edes I, Forster T, Simon K, McDonald K, Maher V, McDonald K, Tavazzi L, Bernobich E, Cucinotta D, Feraco E, Fioretti P, Moretti L, Nami R, Prati C, Rozzini R, Senin U, Tavazzi L, Volpe M, Diaz C, Calvo C, Cruz A, Gomez E, Hernandez I, Meaney E, Orea A, Rosas M, Sanchez C, Villegas E, Cornel J, Bronzwaer P, Cornel J, Cozijnsen L, De Leeuw M, Derks A, DeWaard D, Dunselman P, Freericks M, Hamer B, Hertzberger D, Nagelsmit M, Nierop P, Posma J, Slegers L, Van Asperdt F, Van Daele M, Van Der Linden M, Van Rossum P, Van Veldhuisen D, Verheul J, Wesdorp J, Withagen A, Otterstad J, Aaser E, Otterstad J, Von Brandis C, Ponikowski P, Dluzniewski M, Gaciong Z, Kubica Z, Ogorek M, Ponikowski P, Ruzyllo W, Tendera M, Ujda M, Zalska B, Gomes R, Brito D, Cortez M, Fonseca C, Mareev V, Alexandrov O, Ardashev V, Bart B, Bogoslovskaya SI, Bokarev I, Fitilev S, Fomina I, Glezer M, Goloschekin B, Grineva E, Ivleva A, Kostenko V, Mareev V, Milyagin V, Minkin S, Nosova N, Olbinskaya LI, Orlov V, Perepetch N, Repin M, Ruda M, Sherenkov A, Shlyakhto E, Sidorenko B, Sinopalnikov A, Starodubtsev A, Storozhakov G, Vasyuk Y, Vishnevsky A, Zalevsky G, Zateystchikov D, Dalby A, Dalby A, Libhaber C, Naidoo D, Patel J, Steingo L, Gonzalez-Juanatey J, Anguita Sanchez M, Calvo Gomez C, Casademont J, Conthe P, De Teresa Galvan E, Fernandez JM, Ferreira I, Forteza J, Garcia Puig J, Gonzalez-Juanatey J, Pastor L, Ridocci-Soriano F, Soria F, Suarez C, Zamorano J, Dahlstrom U, Ahlmark G, Boman K, Dahlstrom U, Hglund C, Kahan T, Lycksell M, Saufelberger M, Willenheimer R, Follath F, Gallino A, Estlinbaum W, McDonagh T, Cleland J, McMurray J, Purvis J, Pye M, Stephens J, Kitzman D, O'Connor C, Bouchard A, Goldberg M, Goldman S, Peart B, Wong G, Aude Y, Davidson R, Greenberg B, Massie B, Hagar WD, Adams K, Hendley L, Hilton T, Lakow M, Schneider R, Schocken D, Clemson B, Ortiz J, Bessen M, Ghali J, Iteld B, Weiss R, DiBianco R, Mason S, Porterfield J, Bilazerian S, Semigran M, Desai V, Colfer H, Guglin M, Anand I, Rich M, Chapman D, Reyes A, Graettinger W, Gelernt M, Hettleman B, Orchard R, Baruch L, Benton R, Liang C, Silverman R, Campbell P, Kitzman D, O'Connor C, Sueta C, Amsterdam P, Chung E, Grech D, Traboulssi M, Utlak D, Lewis S, Rodriquez R, Small R, O'Brien T, Zile M, McGrew F, Blois S, Goulah R, Nygaard T, Peberdy M, Stagaman D.

Author information

  • 1University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA. barry.massie@va.gov

Abstract

BACKGROUND:

Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome.

METHODS:

We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life.

RESULTS:

During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes.

CONCLUSIONS:

Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)

2008 Massachusetts Medical Society

Comment in

PMID:
19001508
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk